Exubera Inhaled Insulin Gets Favorable Committee Review In Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
European Medicines Agency's Committee for Medicinal Products for Human Use recommends approval of Pfizer/Sanofi's agent for type 1 and 2 diabetes with post-market monitoring for pulmonary function decline and hypoglycemia.
You may also be interested in...
Exubera Approved In Europe One Day Before U.S. User Fee Date
Pfizer said it is investing in "extensive educational programs" to respond to concerns about the inhaled insulin's dosing mechanism.
Exubera Approved In Europe One Day Before U.S. User Fee Date
Pfizer said it is investing in "extensive educational programs" to respond to concerns about the inhaled insulin's dosing mechanism.
Pfizer/Sanofi Exubera Effective For Both Type 1 And Type 2 Diabetes, Committee Says
Advisory committee rejects FDA contention that inhaled insulin may not have shown intensive glycemic control in Type 1 diabetes.